Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (COMMODORE 3)
NCT04654468Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Roche. Primary endpoints: Mean Percentage of Participants With Hemolysis Control and Difference in Percentage of Participants With Transfusion Avoidance (TA). Started Mar 2021; status: active, not recruiting.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04654468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04654468.